Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T01271 Target Info
Target Name Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)
Synonyms T315I BCR-ABL; BCR-ABL T315I mutant
Target Type Patented-recorded Target
Gene Name BCR-ABL1
Biochemical Class Kinase
UniProt ID
BCR_HUMAN - ABL1_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2013171641
Title Compounds and Compositions for Inhibiting The Activity of Abl1, Abl2 and Bcr-Abl1.
Abstract The present invention relates to compounds of formula I: in which Y, Y1, Y 4, Y5, Y 6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
Applicant(s) Novartis Ag
Representative Drug(s) D09WKF Drug Info IC50 = 61 nM Click to Show More [1]
2 D09ZFM Drug Info IC50 = 306 nM [1]
3 D02KNW Drug Info IC50 = 400 nM [1]
4 D0BK6R Drug Info IC50 = 617 nM [1]
Patent ID WO2013171639
Title Benzamide Derivatives for Inhibiting The Activity of Abl1, Abl2 and Bcr-Abl1.
Abstract The present invention relates to compounds of formula (I): in which Y, Y1, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
Applicant(s) Novartis Ag
Representative Drug(s) D08IUE Drug Info IC50 = 13 nM Click to Show More [1]
2 D0IA4G Drug Info IC50 = 22 nM [1]
3 D01KIJ Drug Info IC50 = 23 nM [1]
Patent ID WO2012004217
Title Cyclic Ether Compounds Useful As Kinase Inhibitors.
Abstract The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof, as further described herein. Also provided are formulations comprising compounds of formula I, and a method to use such compounds for treating a disease or condition mediated by Provirus Integration of Maloney Maloney Kinase (PIM Kinase), GSK3, PKC, KDR, PDGFRa, FGFR3, FLT3, or cABL.
Applicant(s) Novartis Ag
Representative Drug(s) D0FB1Q Drug Info IC50 = 30 nM Click to Show More [1]
2 D01UTX Drug Info IC50 = 70 nM [1]
3 D0H3VI Drug Info IC50 = 70 nM [1]
Patent ID WO2014040549
Title Alkynyl Heteroaromatic Ring Compound and Application Thereof.
Abstract Provided are a class of alkynyl heteroaromatic ring-structured compounds, a pharmaceutically acceptable salt of same, a stereoisomer of same, an N-oxide of same, a solvate of same or a prodrug of same, a pharmaceutical composition having these compounds, and applications of these compounds or of the composition in the preparation of a medicament. The compounds are provided with improved anti-tumor activity.
Applicant(s) Nanjing Sanhome Pharmaceutical Co Ltd
Representative Drug(s) D0C2YI Drug Info IC50 = 2.3 nM [1]
Patent ID WO2010092489
Title Derivatives of Azaindoles As Inhibitors of Protein Kinases Abl and Src.
Abstract The present invention relates to compounds of general formula I and use thereof as inhibitors of protein kinases AbI and Src and the method of production thereof. The present invention also relates to pharmaceutical compositions and medicinal products comprising these compounds.
Applicant(s) Oribase Pharma
Representative Drug(s) D01LMW Drug Info IC50 = 100 to 10000 nM [1]
References  Top
REF 1 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.